Catherine Longworth is a reporter covering commercial and R&D developments in the medtech industry. A graduate of St. George's, University of London, Catherine holds a BSc in Biomedical Science. Before joining Informa, she worked in the editorial team at Pharmaceutical Press, the publishing division of the Royal Pharmaceutical Society, where she wrote and edited for a number of pharmaceutical publications. After gaining experience in the world of scientific publishing, Catherine took the leap to study a postgraduate qualification in journalism. During the course, she carried out placements with local London newspapers, writing general news and building her portfolio by reporting on a wide range of current affairs such as the European migrant crisis, political protests and the London mayoral election. Catherine is passionate about human rights and is fascinated by the innovative nature of the medtech industry and the healthcare advances that have the greatest benefit to mankind. She lives in London and loves music, arts, travel, writing, reading and is always happy to receive recommendations for books or places to travel!
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Catherine Longworth
Boston Scientific has completed the acquisition of UK interventional medicine specialist BTG. The deal, which was announced in November last year is Boston Scientific’s biggest since its controversial 2006 acquisition of heart device maker Guidant Corp. for $27bn.
In this edition of Device Week, Medtech Insight managing editor Marion Webb reports on her discussions with diagnostic company executives at the recent American Association for Clinical Chemistry meeting in Anaheim. And senior reporter Catherine Longworth previews her feature on MDisrupt, a new company that touts itself as the world’s first medical diligence company for the healthcare industry.
AtriCure Inc. has closed a $300m structured deal to acquire SentreHEART Inc., a privately held developer of percutaneous left atrial appendage management solutions.
Siemens Healthineers AG has signed a billion-dollar deal to merge with US firm Corindus Vascular Robotics, expanding the German company's advanced therapies business.
Neuromodulation firm Nexstim has received regulatory clearance for its SmartFocus TMS system for treating major depressive disorder (MDD) in Australia.
Angle is moving closer to becoming the first company to receive US FDA-clearance for a system that captures and harvests intact circulating tumor cells from patient blood for analysis.